Series D – Talk Bio

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

3 months ago talkbio0Tagged Artificial Intelligence, cancer care, Healthcare technology, oncology ecosystem, orchestration, patient navigation, Series D, strategic investors, Thyme Care, unicorn startup, Value-Based Care

Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

3 months ago talkbio0Tagged Biosciences, Dermatitis, Atopic, Enveda, Immune System Diseases, Investments, Mikael, nature-inspired drug discovery, Series D

Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment

Avalyn Pharma Raises $100M to Advance Inhaled Lung Disease Drugs

5 months ago talkbio0Tagged AP01, AP02, aspects of adverse effects, Avalyn, Clinical Trials, drug safety, Holdings, inhaled lung disease, nintedanib, Pharma, pirfenidone, Pulmonary Fibrosis, Series D, SNCG gene, Suvretta Capital Management

Avalyn Pharma; $100 million Series D; inhaled lung disease medications; pulmonary fibrosis; AP01; AP02; pirfenidone; nintedanib; clinical trials; drug safety; side effects; Suvretta Capital Management; SR One; Novo Holdings